Heterocyclic Derivatives for α-Synuclein Aggregate Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's disease lack effective agents to suppress or reduce the accumulation of α-synuclein aggregates, and there is a lack of in vitro evaluation systems to assess the action of such agents.
Innovation Solution
A nitrogen-containing saturated heterocyclyl derivative or its pharmaceutically acceptable salt, which suppresses or reduces the accumulation of abnormal protein aggregates in the brain, and a method to reproduce Parkinson's disease pathology using neurospheroids for evaluating α-synuclein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If in vitro evaluation systems using artificially synthesized α-synuclein oligomers are used, then evaluation can be performed, but the system cannot reproduce endogenous α-synuclein aggregates and cannot accurately evaluate the action of suppressing accumulated aggregates
Solution Approach 1:
The patent uses neurospheroids as a three-dimensional in vitro model that copies and reproduces the endogenous α-synuclein aggregate formation mechanism in the brain. This allows accurate evaluation of compounds' ability to suppress accumulated aggregates, resolving the contradiction between ease of system establishment and measurement precision.
Solution Approach 2:
The patent introduces neurospheroids as an intermediary system between in vitro evaluation and actual brain pathology. The neurospheroids serve as a mediator that reproduces endogenous aggregate formation, enabling precise evaluation of compound efficacy without requiring direct access to brain tissue.
2Object-generated harmful factors
If existing drugs like NPT200-11 and Anle138b are used to inhibit α-synuclein aggregate formation, then aggregate formation can be suppressed in vitro, but the accumulation of aggregates in the brain cannot be reduced
Solution Approach 1:
The patent employs neurospheroids as a feedback system that allows real-time observation and measurement of α-synuclein aggregate accumulation. This enables evaluation of whether compounds can reduce accumulated aggregates in a manner that mirrors actual brain pathology, providing reliable feedback on compound efficacy.
Solution Approach 2:
The patent changes the evaluation parameter from in vitro aggregate formation inhibition to in vivo-like aggregate accumulation reduction using neurospheroids. This parameter change allows assessment of compounds' ability to reduce accumulated aggregates, addressing the limitation of existing drugs.
3Ease of operation
If levodopa is administered for symptomatic therapy, then Parkinson's disease symptoms can be managed, but no fundamental treatment has been established
Solution Approach 1:
The patent uses neurospheroids to copy and reproduce Parkinson's disease pathology, including α-synuclein aggregate accumulation. This allows evaluation of compounds that can fundamentally treat the disease by reducing aggregate accumulation, moving beyond symptomatic therapy to fundamental treatment.
Data Source
AI summary
The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.